Panels and Workshops

BioSquare Sessions: Monday, March 9, 2009

 

 

Panels and Workshops

Parallel One-to-one meetings
10:45 am /12:00pm               

 

Workshop 1  - Comparison between the public financial supports                                          of Biotech

Workshop 2  -  New Antibiotherapies for tomorrow               

Workshop 3 -  The Cleantech Market in Europe

 

 

1:00 pm / 2:15 pm    

Opening Plenary Session 

 

 

2:15 pm / 3:30 pm

Panel 1  -  More R&D investment but no more drugs approved. What’s                           wrong?

Yes
4:00 pm / 5:30 pm

Panel 2  - The Brain Device Interface

Yes
 
5:30 pm / 6:30 pm

Workshop 4 -  New trends in Nanomedicine.What’s new with                                                  miniaturizing?

Workshop 5  - Theranostics

Workshop 6 -  Cellular Therapies, challenging but promising

Yes

Yes

Yes

 

 

company presentations

 

With renowned experts and professionals from the industry, academia, and regulatory bodies, sharing their views and experience, the BioSquare conference analyzes new industry trends and developments and discusses the approaches biotechnology companies can adopt in facing the current challenges. Topics cover partnering, finance and other issues of importance to the biotech industry.

Interactive Workshops: You will be provided with practical tools for problem solving. We specifically limit the number of participants and encourage audience participation.

Panel Discussions: Comprehensive discussion on topics of interest to the entire audience.

 

Panels and Workshops:

Opening Plenary Session - Towards a Bio Economy

Monday, March 9,1:00 pm to 2:15 pm Venue: Auditorium Pasteur,  Lyon Convention Center,  France

Session presentation:

 

Where will be the biotech world in five years from now? There’re reasons to believe it will be converging along two main streams: a/ technological with the multiple synergies between genomics, bioinformatics, modeling sofwares, nanoelectronics, b/ societal through the never-ending vortex of debate between Public policies and regulations, Business needs / opportunities and technological breakthroughs.

Looking ahead, it seems that creative and innovative solutions are mandatory for a continued economic development in a sustainable way.

During the last two decades of the 20st century, the genomics and stem cell revolutions have upset medical discoveries; the 21st century began with prevention and wellness and will move us towards a more personalized medicine world that will transform Healthcare dramatically.

In Agri/Food, new technologies have allowed farmers to increase productivity and to develop crops with higher nutritional value, thus helping to fight malnutrition in an environmentally sustainable way to answer the global needs of a growing population.

Driven by the challenge of developing new sustainable energy sources and climate change, industrial biotechnology now seems to able to bring cleaner and greener solutions to the production of detergents, the clean up of environmental waste, the increase of agro productivity and is now making possible to envision a future where bioenergy will eventually replace fossil fuel energy.

Biotechnology has to provide innovative solutions to a wide range of Health, Agri /Food and Environmental issues in the next five years to come.

 

Confirmed speakers:

  • Marc Cluzel - Senior Vice President Research and Development , Sanofi-aventis
  • Dr Tim Hall,  Acting Director: Biotechnologies, Agriculture and Food, DG Research, European Commission  
  • Steen Riisgaard, CEO Novozymes A/S, Denmark; Chairman, Europabio, Belgium
  • Elias A. Zerhouni, Director, U.S. National Institutes of Health

Moderator: Maria Livanos Cattaui, Member of the Board of Directors, Petroplus Holdings AG

 PANEL N°1 – More R&D investment but no more drugs approved. What’s Wrong?

Monday, March 9,  2.15 pm to 3.30 pm, Venue: "Auditorium Pasteur",  Lyon Convention Center,  France

Session presentation:

There seems to be a bad omen on drug development. Despite the vertiginous rise of “R&D” budgets it looks like fewer treatments are reaching the market. Recent examples of newly approved therapies only to be withdrawn at the first adverse effect even darken the picture. The speakers of this first panel will thus question the actual paradigm of therapeutic discovery and development. 


Confirmed speakers:

  • Richard Seebrook, Head of Business Development Technology Transfer, Wellcome Trust 
  • Ludo Lauwers, Sr. Vice President, Vice Chairman Management Board Janssen Pharmaceutica NV  
  • Daniel Cohen , CEO, Pharnext
  • Mondher Toumi, President and Founder of Creativ-Ceutical
  • Corey Goodman, President, Biotherapeutics and Bioinnovation Center
     

Moderator: Philippe Pouletty , Chairman of France Biotech,Founder and General Partner of Truffle Capital

PANEL N°2 – The Brain Device Interface

Monday, March 9, 4 pm to 5.30 pm, Venue:  "Auditorium Pasteur"  Lyon Convention Center,  France

Session presentation:

Recent successful experiments have shown the public that building a real brain-machine-Interface was not rocket-science. If a monkey can let a robot walk on the opposite side of the earth, when will a paraplegic just stand-up and walk. The participants to this panel will present both on the discovery/innovation side but also on the business opportunity side the most recent development in this new area, also prompting that the interface between the brain and a device of interest does not necessarily imply contact or energy transert. 

Confirmed speakers:

Moderator: Gilles Rubinstenn, CEO, Foundation Pierre-Gilles de Genne

WORKSHOP N°1 – Comparison between the public financial supports of Biotech

Monday, March 9, 10.45 am to 12.00 pm, Venue: "Saint Clair 1"  hall,  Lyon Convention Center,  France

Session presentation:

Developing innovative therapies is not only a business adventure but also a societal crusade. Therefore have most of the developed country established public policies meant to financially support the high risk phases of new treatment discovery, design and validation. The participants to this first Workshop will not only draw a landscape of the public financing inside and outside Europe but also try to answer the question of the efficacy of these policies with respect to the always raising complexity of the regulatory barrier.

Confirmed speakers:

  • Willy De Greef, Secretary General of EuropaBio
  • Mary Beth Totten, Business Development Associate, Massachusetts Office of International Trade & Investment
  • Marie-Laure Muiras, Project Director, ACIES
  • Daniel Vasmant, Head of the Health, Biotechnology and Food Industry department,General Directorate for Competitiveness, Enterprise and Services  of the French Ministry of Economy, Industry and employment

Moderator:  Barend Verachtert, Head of sector - SME - policy issues, Directorate General Research, European Commission

WORKSHOP N°2 – New Antibiotherapies for tomorrow

Monday, March 9, 10.45 am to 12.00 pm, Venue: "Saint Clair 2"  hall,  Lyon Convention Center,  France

Session presentation:

Antibiotic strategies are probably the most ancient medicine as proved the by recent discoveries on the sophisticated NO activating based protection of the “eye gate” by Egyptian kohl. Nevertheless, or maybe because our war against microbe is not new, the XXIst century needs more than ever new antibiotics to fight against new resistances of well known pathogens and the rise of new ones. In parallel there is a real danger of dry-up as conventional ways to design and assess antibiotics seems less and less efficient. During the WORKSHOP N°2 the most advanced and successful approaches as well as the characteristics of future opportunities will be exposed.

Confirmed speakers:

  • Jeff Hillman, Chief Scientific Officer, ONI BioPharma, Inc
  • Peter Hamman, Global infectious disease initiative, co-leader, sanofi-aventis
  • Alan S. Klein, Executive Vice-President, Corporate Development, Sequella
  • Patrice Courvalin, Professor and head of the Antibacterial Agents Unit, National Reference Center for Antibiotics, Institut Pasteur

Moderator: Tim Joslin, Defined Health’s Managing Director, Europe

WORKSHOP N°3 – The Cleantech Market in Europe

Monday, March 9, 10.45 am to 12.00 pm, Venue: "Saint Clair 3 A"  hall,  Lyon Convention Center,  France

Session presentation:

What have the Cleantechs to do with the Biotechs? This question is much less academic than it may appear at first glance. The speakers of the Workshop N°3 will debate along two different lines of relation between those two Markets. Do Cleantechs and Biotech compete, or even maybe cannibalize each-other, for funding? How is triggered this competition? What are the latent synergies between these two markets, set on the same technological roots and tools? How can the Biotech Entrepreneur take the best out of theses synergies?

 Confirmed speakers:

  • François Houssin, Senior Development Manager, European Listing, NYSE Euronext, France
  • Peter Rosholm,  Vice President Biopharma area  - Novozymes
  • Adbelkader Guellil, Akaeno

Moderator: Albin Jourda, Managing Director, Gallium Moore

 

 

WORKSHOP N°4 – New trends in nanomedicine. What's new in miniaturizing?

Monday, March 9, 5.30 pm to 6.30 pm, Venue: "Saint Clair 1"  hall,  Lyon Convention Center,  France

Session presentation:

Alongside the dramatic regulatory maze that face conventional drug development the Medical Device market look like a highway to innovative therapies. Nevertheless new development, particularly when based on the miniaturization of the devices (for instance the uses of nano-particles), or new matter-wave interactions (ultrasound for therapy) raise new questions as well as new opportunities. What are the forecasted evolutions of the regulatory frame to cope with these new solutions? Do we have all the needed tool for straightforward validations of the efficacy and risk assessment? Regulatory expert, Academics and Entrepreneurs will debate on these issues during WORKSHOP N°4.

Confirmed speakers:

Moderator: Bertrand Vigner, McKinsey


WORKSHOP N°5 – Theranostics

 Monday, March 9, 5.30 pm to 6.30 pm, Venue: "Saint Clair 2"  hall,  Lyon Convention Center,  France

Session presentation:

The word Theranostics may be unknown to you even if you are an actor of the biotech industry. It means combining in one single operation, therapy with highly specific diagnostics. It thus covers a large span of potential applications and more interestingly new business opportunities. From individual profiling to fine tune the immunomodulator dosing following organ transplantation to the use of specific antigens for combined cancer treatment and visualization of attack against the targeted tumor, Theranostic seems to enable endless combinations. To identify the most up-to-date opportunities the participants to the WORKSHOP N°5 will be given access to the recent developments on this new market that is also strongly connected with recent sociological and regulatory evolutions.

Confirmed speakers:

Moderator: Dr Simon Burnell, Head of Diagnostics, Cambridge Consultants

WORKSHOP N°6 – Cellular Therapies, challenging but promising

Monday, March 9,  5.30 pm to 6.30 pm, Venue: "Saint Clair 3 A"  hall,  Lyon Convention Center,  France

Session presentation:

We will probably never cure cancer by trying to transfect all mutated cells with a bioengineered vector. But working on somatic or tumorous stem cells, we might very well be able to grow new organs, produce large quantity of bio-active molecules, implant fully bio-compatible medical devices for the long-lasting delivery of endogenous biomolecules, or rebuild deficient immunological or neural systems. This new approaches have also raised philosophical concerns among Europe and the United States raising a high barrier for the development of these therapies. We will discuss these issues and present the challenges and the main opportunities in that field alongside the first clinical validations.

 Confirmed speakers:

 Moderator: Sebastien Dias, McKinsey

 

logos EuropaBio JBA Swiss Biotech Ernst & Young Fondation Pierre Gilles de Gennes France BiotechMinistere de l'économie, de l'industrie et de l'emploi